Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer Meeting Abstract
| Authors: | Hong, D. S.; Xu, R. H.; McDermott, R. S.; Shen, L.; Dierselhuis, M. P.; Doz, F.; Tahara, M.; Bernard-Gauthier, V.; Norenberg, R.; Brega, N.; Laetsch, T. W.; Drilon, A. |
| Abstract Title: | Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S469 |
| Language: | English |
| ACCESSION: | WOS:001087480201009 |
| DOI: | 10.1016/j.annonc.2023.09.1853 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 667P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
